Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

All cancer mutations that cause drug resistance fall into one of four categories. New research has detailed each type, helping to uncover targets for drug development and identify potential effective ...

Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the ...

Innovative application of an existing drug offers promising alternative treatment to traditional chemotherapy for patients with appendix cancer.

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health ...

The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.

Israelis Were Surprised to Discover Sinwar’s Body After Shooting Stopped The soldiers who killed Yahya Sinwar, a major target of Israel’s military campaign in Gaza, had not expected to run ...